Stock RPID RAPID MICRO BIOSYSTEMS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Rapid Micro Biosystems, Inc.

Equities

RPID

US75340L1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.8 USD -1.27% Intraday chart for Rapid Micro Biosystems, Inc. -2.44% +8.11%
May. 03 Transcript : Rapid Micro Biosystems, Inc., Q1 2024 Earnings Call, May 03, 2024
May. 03 Earnings Flash (RPID) RAPID MICRO BIOSYSTEMS Posts Q1 Revenue $5.6M MT

Summary

  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
RAPID MICRO BIOSYSTEMS, INC. Stock Rapid Micro Biosystems, Inc.
+8.11% 34.29M
C-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.78% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. RPID Stock
  4. Ratings Rapid Micro Biosystems, Inc.